Gainers

• Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to $6.63 during Tuesday's pre-market session. The company's market cap stands at $2.9 million.
• Venus Concept (NASDAQ:VERO) stock moved upwards by 24.61% to $2.08. The market value of their outstanding shares is at $3.1 million.
• Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 17.61% to $0.06. The company's market cap stands at $2.0 million.
• uniQure (NASDAQ:QURE) shares moved upwards by 14.88% to $23.47. The market value of their outstanding shares is at $1.2 billion.
• ClearPoint Neuro (NASDAQ:CLPT) shares rose 10.66% to $13.7. The market value of their outstanding shares is at $368.2 million.
• Organogenesis Holdings (NASDAQ:ORGO) stock moved upwards by 10.14% to $5.32. The market value of their outstanding shares is at $612.7 million.

Losers

• Radiopharm Theranostics (NASDAQ:RADX) shares declined by 37.9% to $6.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $82.7 million.
• Zynex (NASDAQ:ZYXI) shares declined by 35.05% to $0.43. The market value of their outstanding shares is at $20.1 million.
• rYojbaba (NASDAQ:RYOJ) shares declined by 17.08% to $3.21. The company's market cap stands at $43.5 million.
• Verrica Pharmaceuticals (NASDAQ:VRCA) shares fell 11.91% to $6.66. The company's market cap stands at $71.7 million.
• Equillium (NASDAQ:EQ) stock declined by 9.84% to $1.1. The company's market cap stands at $74.2 million.
• Aldeyra Therapeutics (NASDAQ:ALDX) shares declined by 9.28% to $3.62. The market value of their outstanding shares is at $240.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.